ArticleArthritis research & therapy2007
Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis.
Article in Arthritis research & therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 77 citations in OpenAlex.
- Improved efficacy and long-term protective effects of CXCR4/IL10 bioengineered mesenchymal stromal cells in a model of inflammatory bowel disease.Bioengineering & translational medicine · 2026Article
- Exploring the mechanism of fibronectin extra domain B in the tumor microenvironment and implications for targeted immunotherapy and diagnostics (Review).Molecular medicine reports · 2025Review
- Protein isoform-centric therapeutics: expanding targets and increasing specificity.Nature reviews. Drug discovery · 2024Review
- IL-10 deficiency aggravates cell senescence and accelerates BLM-induced pulmonary fibrosis in aged mice via PTEN/AKT/ERK pathway.BMC pulmonary medicine · 2024Article
- Sonic vibration ameliorates inflammatory diseases via the up-regulation of IL-10.Animal cells and systems · 2024Article
- Dual Role of Interleukin-10 in Murine NZB/W F1 Lupus.International journal of molecular sciences · 2021Article
- IL10- and IL35-Secreting MutuDC Lines Act in Cooperation to Inhibit Memory T Cell Activation Through LAG-3 Expression.Frontiers in immunology · 2021Article
- Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors.Oncotarget · 2020Article
- Human fibronectin extra domain B as a biomarker for targeted therapy in cancer.Molecular oncology · 2020Review
- Biology and therapeutic potential of interleukin-10.The Journal of experimental medicine · 2020Review
- Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.New biotechnology · 2019Review
- Senescent Cells with Augmented Cytokine Production for Microvascular Bioengineering and Tissue Repairs.Advanced biosystems · 2019Article
- Bioactive factors for cartilage repair and regeneration: Improving delivery, retention, and activity.Acta biomaterialia · 2019Review
- Advances in antibody engineering for rheumatic diseases.Nature reviews. Rheumatology · 2019Review
- Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.Cold Spring Harbor perspectives in biology · 2019Review
- Targeting the extracellular matrix for delivery of bioactive molecules to sites of arthritis.British journal of pharmacology · 2019Review
- Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site.Immunological reviews · 2016Review
- Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Drug discovery today · 2016Review
- Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Journal of clinical pharmacology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antibody-mediated targeted delivery of cytokines to sites of disease is a promising avenue for cancer therapy, but it is largely unexplored for the treatment of chronic inflammatory conditions. Using both radioactive and fluorescent techniques, the human monoclonal antibodies L19 and G11 (specific to two markers of angiogenesis that are virtually undetectable in normal adult tissues) were found to selectively localize at arthritic sites in the murine collagen-induced model of rheumatoid arthritis following intravenous (i.v.) administration. The same animal model was used to study the therapeutic action of the L19 antibody fused to the cytokines IL-2, tumour necrosis factor (TNF) and IL-10. Whereas L19-IL-2 and L19-TNF treatment led to increased arthritic scores and paw swellings, the fusion protein L19-IL-10 displayed a therapeutic activity, which was superior to the activity of IL-10 fused to an antibody of irrelevant specificity in the mouse. The anti-inflammatory cytokine IL-10 has been investigated for the treatment of patients with rheumatoid arthritis, but clinical development plans have been discontinued because of a lack of efficacy. Because the antigen recognised by L19 is strongly expressed at sites of arthritis in humans and identical in both mice and humans, it suggests that the fusion protein L19-IL-10 might help overcome some of the clinical limitations of IL-10 and provide a therapeutic benefit to patients with chronic inflammatory disorders, including arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.